Zolpidem Use and Hip Fractures in Older People
OBJECTIVES: The widespread use of sedative‐hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer regimens that may be used preferentially by older people. Although benzodiazepines have been shown to increase fall and fracture risk, zolpide...
Saved in:
Published in | Journal of the American Geriatrics Society (JAGS) Vol. 49; no. 12; pp. 1685 - 1690 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Boston, MA, USA
Blackwell Science Inc
01.12.2001
Blackwell Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
ISSN | 0002-8614 1532-5415 |
DOI | 10.1111/j.1532-5415.2001.49280.x |
Cover
Abstract | OBJECTIVES: The widespread use of sedative‐hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer regimens that may be used preferentially by older people. Although benzodiazepines have been shown to increase fall and fracture risk, zolpidem, a nonbenzodiazepine hypnotic, has been advocated as a safer alternative.
DESIGN: Case‐control study of hip fracture cases and controls in 1994.
SETTING: All subjects were age 65 and older and enrolled in Medicare, and in Medicaid or the Pharmaceutical Assistance to the Aged and Disabled program of New Jersey.
PARTICIPANTS: Cases (n = 1,222) were patients who underwent surgical repair of a hip fracture. They were frequency‐matched to four controls (n = 4,888) based on age and gender.
MEASUREMENTS: Use of sedative‐hypnotics and other medications was assessed in the 180 days before the index event. We assessed other covariates, including demographic, clinical, and healthcare utilization variables in the prior 180 days.
RESULTS: Zolpidem use was associated with a significant increased risk of hip fracture (adjusted odds ratio (AOR) 1.95; 95% confidence interval (CI) = 1.09–3.51). Other psychotropic medication classes with significantly increased risks included benzodiazepines (AOR 1.46; 95% CI = 1.21–1.76), antipsychotic medications (AOR 1.61; 95% CI = 1.29–2.01), and antidepressants (AOR 1.46; 95% CI = 1.22–1.75). In subanalyses, preferential use of zolpidem by subjects at greater risk of hip fracture did not appear to explain the apparent risk of hip fracture with zolpidem use.
CONCLUSION: Use of zolpidem by older people was associated with nearly twice the risk of hip fracture, even after controlling for possible demographic and clinical confounders. Rather than being a safer alternative, zolpidem may be associated with risks that are as great as those seen with conventional benzodiazepines in older patients. |
---|---|
AbstractList | The widespread use of sedative-hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer regimens that may be used preferentially by older people. Although benzodiazepines have been shown to increase fall and fracture risk, zolpidem, a nonbenzodiazepine hypnotic, has been advocated as a safer alternative.OBJECTIVESThe widespread use of sedative-hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer regimens that may be used preferentially by older people. Although benzodiazepines have been shown to increase fall and fracture risk, zolpidem, a nonbenzodiazepine hypnotic, has been advocated as a safer alternative.Case-control study of hip fracture cases and controls in 1994.DESIGNCase-control study of hip fracture cases and controls in 1994.All subjects were age 65 and older and enrolled in Medicare, and in Medicaid or the Pharmaceutical Assistance to the Aged and Disabled program of New Jersey.SETTINGAll subjects were age 65 and older and enrolled in Medicare, and in Medicaid or the Pharmaceutical Assistance to the Aged and Disabled program of New Jersey.Cases (n=1,222) were patients who underwent surgical repair of a hip fracture. They were frequency-matched to four controls (n=4,888) based on age and gender.PARTICIPANTSCases (n=1,222) were patients who underwent surgical repair of a hip fracture. They were frequency-matched to four controls (n=4,888) based on age and gender.Use of sedative-hypnotics and other medications was assessed in the 180 days before the index event. We assessed other covariates, including demographic, clinical, and healthcare utilization variables in the prior 180 days.MEASUREMENTSUse of sedative-hypnotics and other medications was assessed in the 180 days before the index event. We assessed other covariates, including demographic, clinical, and healthcare utilization variables in the prior 180 days.Zolpidem use was associated with a significant increased risk of hip fracture (adjusted odds ratio (AOR) 1.95; 95% confidence interval (CI)=1.09-3.51). Other psychotropic medication classes with significantly increased risks included benzodiazepines (AOR 1.46; 95% CI=1.21-1.76), antipsychotic medications (AOR 1.61; 95% CI=1.29-2.01), and antidepressants (AOR 1.46; 95% CI=1.22-1.75). In subanalyses, preferential use of zolpidem by subjects at greater risk of hip fracture did not appear to explain the apparent risk of hip fracture with zolpidem use.RESULTSZolpidem use was associated with a significant increased risk of hip fracture (adjusted odds ratio (AOR) 1.95; 95% confidence interval (CI)=1.09-3.51). Other psychotropic medication classes with significantly increased risks included benzodiazepines (AOR 1.46; 95% CI=1.21-1.76), antipsychotic medications (AOR 1.61; 95% CI=1.29-2.01), and antidepressants (AOR 1.46; 95% CI=1.22-1.75). In subanalyses, preferential use of zolpidem by subjects at greater risk of hip fracture did not appear to explain the apparent risk of hip fracture with zolpidem use.Use of zolpidem by older people was associated with nearly twice the risk of hip fracture, even after controlling for possible demographic and clinical confounders. Rather than being a safer alternative, zolpidem may be associated with risks that are as great as those seen with conventional benzodiazepines in older patients.CONCLUSIONUse of zolpidem by older people was associated with nearly twice the risk of hip fracture, even after controlling for possible demographic and clinical confounders. Rather than being a safer alternative, zolpidem may be associated with risks that are as great as those seen with conventional benzodiazepines in older patients. Although benzodiazepines have been shown to increase fall and fracture risk, zolpidem, a nonbenzodiazepine hypnotic has been advocated as a safer alternative. Finds that use of zolpidem by older people was associated with nearly twice the risk of hip fracture, even after controlling for possible demographic and clinical confounders. Rather than being a safer alternative, zolpidem may be associated with risks that are as great as those seen with conventional benzodiazepines in older patients. (Original abstract - amended) The widespread use of sedative-hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer regimens that may be used preferentially by older people. Although benzodiazepines have been shown to increase fall and fracture risk, zolpidem, a nonbenzodiazepine hypnotic, has been advocated as a safer alternative. OBJECTIVES: The widespread use of sedative‐hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer regimens that may be used preferentially by older people. Although benzodiazepines have been shown to increase fall and fracture risk, zolpidem, a nonbenzodiazepine hypnotic, has been advocated as a safer alternative. DESIGN: Case‐control study of hip fracture cases and controls in 1994. SETTING: All subjects were age 65 and older and enrolled in Medicare, and in Medicaid or the Pharmaceutical Assistance to the Aged and Disabled program of New Jersey. PARTICIPANTS: Cases (n = 1,222) were patients who underwent surgical repair of a hip fracture. They were frequency‐matched to four controls (n = 4,888) based on age and gender. MEASUREMENTS: Use of sedative‐hypnotics and other medications was assessed in the 180 days before the index event. We assessed other covariates, including demographic, clinical, and healthcare utilization variables in the prior 180 days. RESULTS: Zolpidem use was associated with a significant increased risk of hip fracture (adjusted odds ratio (AOR) 1.95; 95% confidence interval (CI) = 1.09–3.51). Other psychotropic medication classes with significantly increased risks included benzodiazepines (AOR 1.46; 95% CI = 1.21–1.76), antipsychotic medications (AOR 1.61; 95% CI = 1.29–2.01), and antidepressants (AOR 1.46; 95% CI = 1.22–1.75). In subanalyses, preferential use of zolpidem by subjects at greater risk of hip fracture did not appear to explain the apparent risk of hip fracture with zolpidem use. CONCLUSION: Use of zolpidem by older people was associated with nearly twice the risk of hip fracture, even after controlling for possible demographic and clinical confounders. Rather than being a safer alternative, zolpidem may be associated with risks that are as great as those seen with conventional benzodiazepines in older patients. OBJECTIVES: The widespread use of sedative‐hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer regimens that may be used preferentially by older people. Although benzodiazepines have been shown to increase fall and fracture risk, zolpidem, a nonbenzodiazepine hypnotic, has been advocated as a safer alternative. DESIGN: Case‐control study of hip fracture cases and controls in 1994. SETTING: All subjects were age 65 and older and enrolled in Medicare, and in Medicaid or the Pharmaceutical Assistance to the Aged and Disabled program of New Jersey. PARTICIPANTS: Cases (n = 1,222) were patients who underwent surgical repair of a hip fracture. They were frequency‐matched to four controls (n = 4,888) based on age and gender. MEASUREMENTS: Use of sedative‐hypnotics and other medications was assessed in the 180 days before the index event. We assessed other covariates, including demographic, clinical, and healthcare utilization variables in the prior 180 days. RESULTS: Zolpidem use was associated with a significant increased risk of hip fracture (adjusted odds ratio (AOR) 1.95; 95% confidence interval (CI) = 1.09–3.51). Other psychotropic medication classes with significantly increased risks included benzodiazepines (AOR 1.46; 95% CI = 1.21–1.76), antipsychotic medications (AOR 1.61; 95% CI = 1.29–2.01), and antidepressants (AOR 1.46; 95% CI = 1.22–1.75). In subanalyses, preferential use of zolpidem by subjects at greater risk of hip fracture did not appear to explain the apparent risk of hip fracture with zolpidem use. CONCLUSION: Use of zolpidem by older people was associated with nearly twice the risk of hip fracture, even after controlling for possible demographic and clinical confounders. Rather than being a safer alternative, zolpidem may be associated with risks that are as great as those seen with conventional benzodiazepines in older patients. The widespread use of sedative-hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer regimens that may be used preferentially by older people. Although benzodiazepines have been shown to increase fall and fracture risk, zolpidem, a nonbenzodiazepine hypnotic, has been advocated as a safer alternative. Case-control study of hip fracture cases and controls in 1994. All subjects were age 65 and older and enrolled in Medicare, and in Medicaid or the Pharmaceutical Assistance to the Aged and Disabled program of New Jersey. Cases (n=1,222) were patients who underwent surgical repair of a hip fracture. They were frequency-matched to four controls (n=4,888) based on age and gender. Use of sedative-hypnotics and other medications was assessed in the 180 days before the index event. We assessed other covariates, including demographic, clinical, and healthcare utilization variables in the prior 180 days. Zolpidem use was associated with a significant increased risk of hip fracture (adjusted odds ratio (AOR) 1.95; 95% confidence interval (CI)=1.09-3.51). Other psychotropic medication classes with significantly increased risks included benzodiazepines (AOR 1.46; 95% CI=1.21-1.76), antipsychotic medications (AOR 1.61; 95% CI=1.29-2.01), and antidepressants (AOR 1.46; 95% CI=1.22-1.75). In subanalyses, preferential use of zolpidem by subjects at greater risk of hip fracture did not appear to explain the apparent risk of hip fracture with zolpidem use. Use of zolpidem by older people was associated with nearly twice the risk of hip fracture, even after controlling for possible demographic and clinical confounders. Rather than being a safer alternative, zolpidem may be associated with risks that are as great as those seen with conventional benzodiazepines in older patients. |
Author | Avorn, Jerry Glynn, Robert J. Wang, Philip S. Bohn, Rhonda L. Mogun, Helen |
Author_xml | – sequence: 1 givenname: Philip S. surname: Wang fullname: Wang, Philip S. organization: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts – sequence: 2 givenname: Rhonda L. surname: Bohn fullname: Bohn, Rhonda L. organization: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts – sequence: 3 givenname: Robert J. surname: Glynn fullname: Glynn, Robert J. organization: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts – sequence: 4 givenname: Helen surname: Mogun fullname: Mogun, Helen organization: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts – sequence: 5 givenname: Jerry surname: Avorn fullname: Avorn, Jerry organization: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13413514$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11844004$$D View this record in MEDLINE/PubMed |
BookMark | eNqV0U9rFDEYBvAgFbutfgUZBL3NmDd_dpKLoMVuK2Vb0KL0EjJJFrJmZ8ZkBrff3kx320Ivai4J5JcnJM8ROmi71iFUAK4gj_frCjglJWfAK4IxVEwSgavtMzR72DhAM4wxKcUc2CE6SmmdIcFCvECHAIIxjNkMVTdd6L11m-I6uUK3tjjzfXEatRnG6FLh2-IyWBeLK9f1wb1Ez1c6JPdqPx-j69PP307OyovLxfnJx4vScC5wSaixUjLcME24AU4MOMKBu3pFGyK1FQxLQ8BiYcBK2gC2rm6s1ELquQZ6jN7tcvvY_RpdGtTGJ-NC0K3rxqRqwqikbP5XyGsBQhKa4ZsncN2Nsc2PUAQwFTmLZPR6j8Zm46zqo9_oeKvu_yuDt3ugk9FhFXVrfHp0lAHlMDmxcyZ2KUW3eiRYTRWqtZqaUlNTaqpQ3VWotvnohydHjR_04Lt2iNqH_wj47YO7_eeL1ZfF17tlDih3AT4NbvsQoONPNa9pzdX35UL9WNKlkFc36hP9A3WUv6o |
CODEN | JAGSAF |
CitedBy_id | crossref_primary_10_1038_s41598_019_56108_4 crossref_primary_10_1097_JCP_0b013e31817d5943 crossref_primary_10_1136_bmjopen_2012_000850 crossref_primary_10_1111_j_1365_2796_2006_01695_x crossref_primary_10_1007_s00198_013_2612_2 crossref_primary_10_1016_j_mayocp_2014_03_006 crossref_primary_10_1111_j_1532_5415_2011_03591_x crossref_primary_10_1155_2022_6168199 crossref_primary_10_1002_14651858_CD005185_pub2 crossref_primary_10_2146_ajhp090611 crossref_primary_10_1007_s00108_010_2647_9 crossref_primary_10_2165_00023210_200721110_00006 crossref_primary_10_1016_j_jcgg_2012_12_001 crossref_primary_10_1007_s40520_022_02237_2 crossref_primary_10_1111_jgs_15438 crossref_primary_10_1002_mpr_1384 crossref_primary_10_2217_pgs_2017_0018 crossref_primary_10_1002_pds_1200 crossref_primary_10_1007_s40429_018_0218_7 crossref_primary_10_1016_j_brat_2013_09_006 crossref_primary_10_21037_ajo_2019_03_01 crossref_primary_10_1002_pds_4706 crossref_primary_10_1016_j_exger_2020_110962 crossref_primary_10_1007_s13181_013_0294_y crossref_primary_10_1007_s00198_005_0065_y crossref_primary_10_1016_j_sleep_2006_01_003 crossref_primary_10_1517_14728214_2012_690735 crossref_primary_10_1007_s00198_008_0711_2 crossref_primary_10_2217_ahe_13_34 crossref_primary_10_5812_ijpbs_9979 crossref_primary_10_1186_s12877_022_02757_6 crossref_primary_10_1016_j_cger_2007_08_012 crossref_primary_10_1016_j_eurger_2012_04_007 crossref_primary_10_1111_jgs_13823 crossref_primary_10_1111_j_1755_5949_2010_00158_x crossref_primary_10_1080_13696998_2018_1466710 crossref_primary_10_1093_sleep_zsab064 crossref_primary_10_1007_s00391_017_1329_9 crossref_primary_10_1002_jhm_1985 crossref_primary_10_1007_s11096_017_0533_4 crossref_primary_10_1186_s12877_018_0972_3 crossref_primary_10_1016_j_bone_2005_07_005 crossref_primary_10_1097_JGP_0b013e31817c6a99 crossref_primary_10_1093_sleep_zsaa093 crossref_primary_10_1177_0898264315618921 crossref_primary_10_1111_j_1745_7599_2007_00285_x crossref_primary_10_1111_j_1532_5415_2006_01006_x crossref_primary_10_1177_00914150221128971 crossref_primary_10_1177_104990910302000512 crossref_primary_10_1016_j_hfc_2010_08_009 crossref_primary_10_2165_00128413_200213240_00053 crossref_primary_10_1007_s00167_010_1368_x crossref_primary_10_1046_j_0306_5251_2003_01852_x crossref_primary_10_2165_00023210_200418050_00003 crossref_primary_10_1177_0897190019851888 crossref_primary_10_1200_JCO_2005_02_8514 crossref_primary_10_1002_pds_2031 crossref_primary_10_2165_00002018_200730020_00006 crossref_primary_10_2165_00002512_200623010_00003 crossref_primary_10_1016_j_cger_2017_06_009 crossref_primary_10_1016_S0924_9338_03_00031_2 crossref_primary_10_1016_j_amjopharm_2006_06_006 crossref_primary_10_1016_j_sleep_2008_04_002 crossref_primary_10_1111_j_1479_8425_2012_00573_x crossref_primary_10_1016_j_ncl_2012_08_012 crossref_primary_10_1093_ageing_aft089 crossref_primary_10_1248_yakushi_18_00156 crossref_primary_10_1007_s00198_016_3881_3 crossref_primary_10_1056_NEJMoa052827 crossref_primary_10_1371_journal_pone_0191211 crossref_primary_10_1155_2019_4306463 crossref_primary_10_1097_01_ede_0000147164_11879_b5 crossref_primary_10_1007_s11910_006_0051_6 crossref_primary_10_1007_s00198_016_3605_8 crossref_primary_10_1371_journal_pone_0174730 crossref_primary_10_1002_j_2055_2335_2007_tb00754_x crossref_primary_10_1002_hup_2219 crossref_primary_10_1016_j_clinthera_2006_08_006 crossref_primary_10_1517_14656566_2012_667074 crossref_primary_10_1016_j_ajem_2008_12_020 crossref_primary_10_1176_appi_ps_201700095 crossref_primary_10_1016_j_addbeh_2012_06_015 crossref_primary_10_2165_11317610_000000000_00000 crossref_primary_10_1586_17512433_2014_864949 crossref_primary_10_1016_j_injury_2021_09_036 crossref_primary_10_1089_pop_2008_0047 crossref_primary_10_1016_j_jamda_2009_10_001 crossref_primary_10_1345_aph_1Q589 crossref_primary_10_4140_TCP_n_2006_293 crossref_primary_10_2217_1745509X_2_1_87 crossref_primary_10_3349_ymj_2015_56_3_772 crossref_primary_10_1176_appi_ps_56_3_332 crossref_primary_10_1016_j_jamda_2017_09_015 crossref_primary_10_1007_s00228_021_03241_7 crossref_primary_10_1186_1478_7954_4_15 crossref_primary_10_2515_therapie_2005078 crossref_primary_10_1007_s40501_013_0004_z crossref_primary_10_2165_00128415_200208880_00004 crossref_primary_10_1007_s00198_007_0375_3 crossref_primary_10_1007_s00198_013_2446_y crossref_primary_10_1038_sj_ki_5002548 crossref_primary_10_12688_f1000research_8729_3 crossref_primary_10_1016_S1543_5946_04_90008_6 crossref_primary_10_12688_f1000research_8729_2 crossref_primary_10_12688_f1000research_8729_1 crossref_primary_10_1097_MJT_0000000000000670 crossref_primary_10_1093_gerona_62_10_1172 crossref_primary_10_1185_030079907X178874 crossref_primary_10_1248_yakushi_20_00018 crossref_primary_10_1097_01_jcp_0000145344_76288_39 crossref_primary_10_1371_journal_pone_0129366 crossref_primary_10_2174_1876818001001010001 crossref_primary_10_1016_j_ajem_2017_04_023 crossref_primary_10_1016_j_amjopharm_2007_09_004 crossref_primary_10_1186_1471_2318_4_9 crossref_primary_10_5664_jcsm_10132 crossref_primary_10_1007_s00198_012_2015_9 crossref_primary_10_1016_j_jhep_2012_12_001 crossref_primary_10_1097_NMD_0b013e3181e9daf7 crossref_primary_10_1016_j_smrv_2023_101866 crossref_primary_10_1016_j_jsmc_2014_11_002 crossref_primary_10_1371_journal_pone_0190022 crossref_primary_10_3389_fphar_2024_1432726 crossref_primary_10_1177_070674370605100504 crossref_primary_10_1186_1471_2318_8_15 crossref_primary_10_1073_pnas_1907354116 crossref_primary_10_1177_0091415016685330 crossref_primary_10_1146_annurev_med_57_071604_141451 crossref_primary_10_1007_s40266_018_0561_3 crossref_primary_10_1186_s12877_017_0530_4 crossref_primary_10_1371_journal_pone_0146030 crossref_primary_10_1007_s40268_017_0207_7 crossref_primary_10_1016_j_amjopharm_2011_10_002 crossref_primary_10_1016_S0029_6465_02_00028_2 crossref_primary_10_1007_s00223_012_9603_8 crossref_primary_10_1016_j_amjopharm_2009_05_002 crossref_primary_10_1111_jgs_15066 crossref_primary_10_1007_s40263_022_00980_8 crossref_primary_10_1186_s13063_017_2001_9 crossref_primary_10_47795_ESUV5344 crossref_primary_10_1111_jgs_14253 crossref_primary_10_1111_j_1532_5415_2005_53303_x crossref_primary_10_1017_S1041610210001547 crossref_primary_10_1186_s40794_017_0054_0 crossref_primary_10_1002_gps_2569 crossref_primary_10_1016_j_jad_2011_10_016 crossref_primary_10_1016_S0749_0690_03_00044_2 crossref_primary_10_1177_0898264318795567 crossref_primary_10_1016_j_amjopharm_2006_09_010 crossref_primary_10_1016_j_amjopharm_2011_10_004 crossref_primary_10_1016_j_metabol_2017_12_002 crossref_primary_10_1093_sleep_zsaa080 crossref_primary_10_1016_S0140_6736_11_60750_2 crossref_primary_10_1002_j_2055_2335_2008_tb00823_x crossref_primary_10_1016_j_bmcl_2005_05_104 crossref_primary_10_1007_s00213_021_05954_0 crossref_primary_10_1007_s00228_012_1424_1 crossref_primary_10_2165_00002512_200522090_00004 crossref_primary_10_1097_YIC_0000000000000221 crossref_primary_10_1007_s00223_004_0258_y crossref_primary_10_3310_hta25010 crossref_primary_10_1111_j_1532_5415_2010_03229_x crossref_primary_10_1002_gps_2189 crossref_primary_10_1016_j_jsmc_2009_01_012 crossref_primary_10_5665_sleep_3566 crossref_primary_10_5665_sleep_5742 crossref_primary_10_1097_MD_0000000000000809 crossref_primary_10_1038_sj_clpt_6100249 crossref_primary_10_1097_00013614_200607000_00005 crossref_primary_10_1136_dtb_2004_421289 crossref_primary_10_1002_pds_3951 crossref_primary_10_1002_14651858_CD010703_pub2 |
Cites_doi | 10.1177/026988119901300109 10.1001/jama.262.23.3303 10.1016/S0924-9338(97)80017-X 10.1097/00004850-199807000-00002 10.1111/j.1532-5415.1999.tb01898.x 10.2165/00003495-199040020-00008 10.1056/NEJM199809243391303 10.1016/0140-6736(92)91935-2 10.1093/ajhp/53.21.2638 10.1056/NEJM198702123160702 10.2165/00002018-199513040-00005 10.2165/00003088-199529030-00002 10.1111/j.1532-5415.1999.tb01603.x 10.1016/S0091-3057(98)00102-6 10.1345/aph.17111 10.1016/0140-6736(93)92862-N 10.1016/0021-9681(87)90171-8 10.1016/0895-4356(92)90133-8 10.5694/j.1326-5377.1993.tb121839.x 10.1001/archinte.155.16.1801 10.1177/106002809703100518 10.1001/archinte.151.9.1779 10.1001/jama.272.22.1721 |
ContentType | Journal Article |
Copyright | 2002 INIST-CNRS Copyright Lippincott Williams & Wilkins Dec 2001 |
Copyright_xml | – notice: 2002 INIST-CNRS – notice: Copyright Lippincott Williams & Wilkins Dec 2001 |
DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QP 7TK K9. NAPCQ 7QJ 7X8 |
DOI | 10.1111/j.1532-5415.2001.49280.x |
DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Neurosciences Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Applied Social Sciences Index & Abstracts (ASSIA) MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Applied Social Sciences Index and Abstracts (ASSIA) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Applied Social Sciences Index and Abstracts (ASSIA) ProQuest Health & Medical Complete (Alumni) CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1532-5415 |
EndPage | 1690 |
ExternalDocumentID | 98663536 11844004 13413514 10_1111_j_1532_5415_2001_49280_x JGS49280 ark_67375_WNG_XN3N89PZ_B |
Genre | shortCommunication Research Support, U.S. Gov't, P.H.S Journal Article Comparative Study Feature |
GrantInformation_xml | – fundername: NIDA NIH HHS grantid: R01 DA100014-01 – fundername: NIA NIH HHS grantid: R03-AG 18395 |
GroupedDBID | --- --Z -~X ..I .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1CY 1KJ 1OB 1OC 29L 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8F7 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANHP AANLZ AAONW AAQQT AASGY AAWTL AAXRX AAYCA AAYJJ AAZKR ABCQN ABCUV ABDPE ABEML ABIVO ABJNI ABLJU ABOCM ABPPZ ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFO ACGFS ACGOF ACHQT ACMXC ACNCT ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEFGJ AEGXH AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFEBI AFFNX AFFPM AFGKR AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHMBA AI. AIACR AIAGR AIDQK AIDYY AIQQE AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BKOMP BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 DUUFO EBS EJD EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ H~9 IHE IX1 J0M J5H K48 KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NHB O66 O9- OHT OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TAE TEORI TN5 TWZ UB1 UKR UPT V9Y VH1 W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WOHZO WOW WQ9 WQJ WVDHM WXI WXSBR X7M XG1 XOL YF5 YFH YOC YQJ YQT YUY YZZ ZGI ZHY ZXP ZY1 ZZTAW ~IA ~S- ~WT AAHHS AARRQ ACCFJ AEEZP AEQDE AEUQT AFPWT AIWBW AJBDE EMOBN ESX QN7 WRC YCJ AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM PKN YIN Z5M 7QP 7TK K9. NAPCQ 7QJ 7X8 |
ID | FETCH-LOGICAL-c5580-23cd9940b4a25c152c1e2515e7f3b29ad8409c21d08c1d93b10de7bd9a89a6a13 |
IEDL.DBID | DR2 |
ISSN | 0002-8614 |
IngestDate | Sun Sep 28 06:37:13 EDT 2025 Sun Sep 28 06:32:39 EDT 2025 Fri Jul 25 08:32:47 EDT 2025 Wed Feb 19 02:35:58 EST 2025 Tue Jul 01 05:45:04 EDT 2025 Tue Jul 01 02:50:52 EDT 2025 Thu Apr 24 23:07:33 EDT 2025 Wed Jan 22 16:58:04 EST 2025 Sun Sep 21 06:18:17 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Keywords | Human Femoral neck Diseases of the osteoarticular system Hypnotic Fracture Case control study Trauma Hip Recommendation Medical prescription Risk factor Secondary effect Zolpidem Fall Bone Elderly |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5580-23cd9940b4a25c152c1e2515e7f3b29ad8409c21d08c1d93b10de7bd9a89a6a13 |
Notes | istex:5AFFC27AA0CFA927C17A9EE6B3AD547A6D5D0762 ArticleID:JGS49280 ark:/67375/WNG-XN3N89PZ-B SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 |
PMID | 11844004 |
PQID | 210384632 |
PQPubID | 41968 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_72439346 proquest_miscellaneous_57818923 proquest_journals_210384632 pubmed_primary_11844004 pascalfrancis_primary_13413514 crossref_primary_10_1111_j_1532_5415_2001_49280_x crossref_citationtrail_10_1111_j_1532_5415_2001_49280_x wiley_primary_10_1111_j_1532_5415_2001_49280_x_JGS49280 istex_primary_ark_67375_WNG_XN3N89PZ_B |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | December 2001 |
PublicationDateYYYYMMDD | 2001-12-01 |
PublicationDate_xml | – month: 12 year: 2001 text: December 2001 |
PublicationDecade | 2000 |
PublicationPlace | Boston, MA, USA |
PublicationPlace_xml | – name: Boston, MA, USA – name: Malden, MA – name: United States – name: New York |
PublicationTitle | Journal of the American Geriatrics Society (JAGS) |
PublicationTitleAlternate | Journal of the American Geriatrics Society |
PublicationYear | 2001 |
Publisher | Blackwell Science Inc Blackwell Wiley Subscription Services, Inc |
Publisher_xml | – name: Blackwell Science Inc – name: Blackwell – name: Wiley Subscription Services, Inc |
References | Lobo BL & Greene WL. Zolpidem: Distinct from triazolam? Ann Pharmacother 1997;31: 625-632. American Medical Association. Physicians' Current Procedural Terminology, 4th Ed. Chicago, IL: American Medical Association, 1989. Leipzig RM, Cummings RG, Tinetti ME. Drugs and falls in older people: A systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999;47: 30-39. SAS Institute. SAS release 6.12. Cary, NC: SAS Institute, Inc., 1996. International Classification of Diseases, 9th Revision, Clinical Modifications, Vol. 1. Diseases: Tabular List. Commission on Professional and Hospital Activities. Ann Arbor, MI: Edwards Brothers, 1986. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989;262: 3303-3307.DOI: 10.1001/jama.262.23.3303 Langtry HD & Benfield P. Zolpidem: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990;40: 291-313. Baron JA, Lu-Yao G, Barrett J et al. Internal validation of Medicare claims data. Epidemiology 1994;5: 541-544. Guerault E, Chaumet-Riffaud A, Morselli P et al. Neurological adverse event profile in elderly with zolpidem 5 mg and 10 mg: A retrospective evaluation of European phase II and III studies. J Sleep Res 1992;1(Suppl. 1):89. Salva P & Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem: Therapeutic implications. Clin Pharmacokinet 1995;29: 142-153. Cumming RG & Klineberg RJ. Psychotropics, thiazide diuretics and hip fractures in the elderly. Med J Aust 1993;158: 414-417. Mendelson WB & Jain B. An assessment of short-acting hypnotics. Drug Safety 1995;13: 257-270. Wysowski DK & Baum C. Outpatient use of prescription sedative-hypnotic drugs in the United States, 1970 through 1989. Arch Intern Med 1991;151: 1779-1783.DOI: 10.1001/archinte.151.9.1779 Herings RC, Stricker BH, De Boer A et al. Benzodiazepines and the risk of hip falling leading to femur fractures. Arch Intern Med 1995;155: 1801-1807.DOI: 10.1001/archinte.155.16.1801 Charlson ME, Pompei KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 1987;40: 373-383. Hajak G & Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: A post-marketing surveillance of 16,944 cases. Int Clin Psychopharmacol 1998;13: 157-167. Psaty BM, Koepsell TD, Lin D et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 1999;47: 749-754. Salzman C, ed. Clinical Geriatric Psychopharmacology, 3rd Ed. Baltimore, MD: Williams and Wilkins, 1998. Thapa PB, Gideon P, Cost TW et al. Antidepressants and the risk of falls among nursing home residents. N Engl J Med 1998;339: 875-882.DOI: 10.1056/NEJM199809243391303 Rush CR. Behavioral pharmacology of zolpidem relative to benzodiazepines: A review. Pharmacol Biochem Behav 1998;61: 253-269.DOI: 10.1016/S0091-3057(98)00102-6 Gericke CA & Ludolph AC. Chronic abuse of zolpidem. JAMA 1994;272: 1721-1722.DOI: 10.1001/jama.272.22.1721 Ray WA, Griffin MR, Schaffner W et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987;316: 363-369. Iruela L, Ibanez-Rojo V, Baca E. Zolpidem induced macropsia in anorexic woman. Lancet 1993;342: 443-444.DOI: 10.1016/0140-6736(93)92862-N Darcourt G, Pringuey D, Salliere D et al. The safety and tolerability of zolpidem-an update. J Psychopharmacol 1999;13: 81-93. Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: Alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 1998;32: 680-691.DOI: 10.1345/aph.17111 Ansseau M, Pitchot W, Hansemme M et al. Psychotic reactions to zolpidem. Lancet 1992;339: 809.DOI: 10.1016/0140-6736(92)91935-2 Buzo Sanchez LG, Sanchez JM, Moreno JL. Dependence and tolerance with zolpidem. Am J Health Syst Pharm 1996;53: 2638. Hoehns JD & Perry PJ. Zolpidem: A nonbenzodiazepine hypnotic for treatment of insomnia. Clin Pharm 1993;12: 814-828. Walker AM. Observation and Inference: An Introduction to the Methods of Epidemiology. Newton Lower Falls, MA: Epidemiology Resources, 1991, pp 119-128. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45: 613-619.DOI: 10.1016/0895-4356(92)90133-8 Jonas JM, Coleman BS, Sheridan AQ et al. Comparative clinical profiles of triazolam versus other shorter-acting hypnotics. J Clin Psychiatry 1992;53(Suppl):19-31. Allain H & Monti J. General safety profile of zolpidem: Safety in elderly, overdose and rebound effects. Eur Psychiatry 1997;12(Suppl. 1):21S-29S.DOI: 10.1016/S0924-9338(97)80017-X 1991; 151 1995; 13 1999; 47 1994; 272 1998; 339 1998 1996 1994 1995; 155 1998; 61 1991 1992; 53 1996; 53 1993; 342 1990; 40 1993; 12 1987; 40 1997; 31 1989; 262 1987; 316 1997; 12 1999; 13 1986 1992; 339 1995; 29 1993; 158 1998; 32 1992; 45 1992; 1 1994; 5 1989 1988 1998; 13 International Classification of Diseases, 9th Revision, Clinical Modifications, Vol. 1 (e_1_2_6_28_2) 1986 SAS Institute (e_1_2_6_33_2) 1996 e_1_2_6_31_2 Baron JA (e_1_2_6_30_2) 1994; 5 Hoehns JD (e_1_2_6_16_2) 1993; 12 e_1_2_6_18_2 e_1_2_6_19_2 e_1_2_6_12_2 e_1_2_6_13_2 e_1_2_6_34_2 Darcourt G (e_1_2_6_11_2) 1999; 13 e_1_2_6_32_2 Guerault E (e_1_2_6_36_2) 1992; 1 e_1_2_6_17_2 e_1_2_6_14_2 e_1_2_6_15_2 Palminteri R (e_1_2_6_10_2) 1988 Salzman C (e_1_2_6_38_2) 1998 Walker AM (e_1_2_6_35_2) 1991 e_1_2_6_8_2 e_1_2_6_7_2 Griso JA (e_1_2_6_37_2) 1994 e_1_2_6_9_2 e_1_2_6_4_2 e_1_2_6_3_2 American Medical Association (e_1_2_6_29_2) 1989 e_1_2_6_6_2 e_1_2_6_5_2 e_1_2_6_23_2 e_1_2_6_2_2 e_1_2_6_22_2 e_1_2_6_21_2 Jonas JM (e_1_2_6_20_2) 1992; 53 Buzo Sanchez LG (e_1_2_6_24_2) 1996; 53 e_1_2_6_27_2 e_1_2_6_26_2 e_1_2_6_25_2 |
References_xml | – reference: Jonas JM, Coleman BS, Sheridan AQ et al. Comparative clinical profiles of triazolam versus other shorter-acting hypnotics. J Clin Psychiatry 1992;53(Suppl):19-31. – reference: Thapa PB, Gideon P, Cost TW et al. Antidepressants and the risk of falls among nursing home residents. N Engl J Med 1998;339: 875-882.DOI: 10.1056/NEJM199809243391303 – reference: Ray WA, Griffin MR, Schaffner W et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987;316: 363-369. – reference: Hajak G & Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: A post-marketing surveillance of 16,944 cases. Int Clin Psychopharmacol 1998;13: 157-167. – reference: Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989;262: 3303-3307.DOI: 10.1001/jama.262.23.3303 – reference: Walker AM. Observation and Inference: An Introduction to the Methods of Epidemiology. Newton Lower Falls, MA: Epidemiology Resources, 1991, pp 119-128. – reference: Leipzig RM, Cummings RG, Tinetti ME. Drugs and falls in older people: A systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999;47: 30-39. – reference: Buzo Sanchez LG, Sanchez JM, Moreno JL. Dependence and tolerance with zolpidem. Am J Health Syst Pharm 1996;53: 2638. – reference: Wysowski DK & Baum C. Outpatient use of prescription sedative-hypnotic drugs in the United States, 1970 through 1989. Arch Intern Med 1991;151: 1779-1783.DOI: 10.1001/archinte.151.9.1779 – reference: Allain H & Monti J. General safety profile of zolpidem: Safety in elderly, overdose and rebound effects. Eur Psychiatry 1997;12(Suppl. 1):21S-29S.DOI: 10.1016/S0924-9338(97)80017-X – reference: Rush CR. Behavioral pharmacology of zolpidem relative to benzodiazepines: A review. Pharmacol Biochem Behav 1998;61: 253-269.DOI: 10.1016/S0091-3057(98)00102-6 – reference: Psaty BM, Koepsell TD, Lin D et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 1999;47: 749-754. – reference: Hoehns JD & Perry PJ. Zolpidem: A nonbenzodiazepine hypnotic for treatment of insomnia. Clin Pharm 1993;12: 814-828. – reference: Langtry HD & Benfield P. Zolpidem: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990;40: 291-313. – reference: Baron JA, Lu-Yao G, Barrett J et al. Internal validation of Medicare claims data. Epidemiology 1994;5: 541-544. – reference: Cumming RG & Klineberg RJ. Psychotropics, thiazide diuretics and hip fractures in the elderly. Med J Aust 1993;158: 414-417. – reference: Salva P & Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem: Therapeutic implications. Clin Pharmacokinet 1995;29: 142-153. – reference: American Medical Association. Physicians' Current Procedural Terminology, 4th Ed. Chicago, IL: American Medical Association, 1989. – reference: Gericke CA & Ludolph AC. Chronic abuse of zolpidem. JAMA 1994;272: 1721-1722.DOI: 10.1001/jama.272.22.1721 – reference: Lobo BL & Greene WL. Zolpidem: Distinct from triazolam? Ann Pharmacother 1997;31: 625-632. – reference: Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45: 613-619.DOI: 10.1016/0895-4356(92)90133-8 – reference: Iruela L, Ibanez-Rojo V, Baca E. Zolpidem induced macropsia in anorexic woman. Lancet 1993;342: 443-444.DOI: 10.1016/0140-6736(93)92862-N – reference: Darcourt G, Pringuey D, Salliere D et al. The safety and tolerability of zolpidem-an update. J Psychopharmacol 1999;13: 81-93. – reference: Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: Alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 1998;32: 680-691.DOI: 10.1345/aph.17111 – reference: Mendelson WB & Jain B. An assessment of short-acting hypnotics. Drug Safety 1995;13: 257-270. – reference: Ansseau M, Pitchot W, Hansemme M et al. Psychotic reactions to zolpidem. Lancet 1992;339: 809.DOI: 10.1016/0140-6736(92)91935-2 – reference: Guerault E, Chaumet-Riffaud A, Morselli P et al. Neurological adverse event profile in elderly with zolpidem 5 mg and 10 mg: A retrospective evaluation of European phase II and III studies. J Sleep Res 1992;1(Suppl. 1):89. – reference: Charlson ME, Pompei KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 1987;40: 373-383. – reference: International Classification of Diseases, 9th Revision, Clinical Modifications, Vol. 1. Diseases: Tabular List. Commission on Professional and Hospital Activities. Ann Arbor, MI: Edwards Brothers, 1986. – reference: SAS Institute. SAS release 6.12. Cary, NC: SAS Institute, Inc., 1996. – reference: Herings RC, Stricker BH, De Boer A et al. Benzodiazepines and the risk of hip falling leading to femur fractures. Arch Intern Med 1995;155: 1801-1807.DOI: 10.1001/archinte.155.16.1801 – reference: Salzman C, ed. Clinical Geriatric Psychopharmacology, 3rd Ed. Baltimore, MD: Williams and Wilkins, 1998. – volume: 13 start-page: 257 year: 1995 end-page: 270 article-title: An assessment of short‐acting hypnotics. publication-title: Drug Safety – volume: 29 start-page: 142 year: 1995 end-page: 153 article-title: Clinical pharmacokinetics and pharmacodynamics of zolpidem: Therapeutic implications. publication-title: Clin Pharmacokinet – volume: 1 start-page: 89 issue: Suppl. 1 year: 1992 article-title: Neurological adverse event profile in elderly with zolpidem 5 mg and 10 mg: A retrospective evaluation of European phase II and III studies. publication-title: J Sleep Res – year: 1989 – volume: 158 start-page: 414 year: 1993 end-page: 417 article-title: Psychotropics, thiazide diuretics and hip fractures in the elderly. publication-title: Med J Aust – volume: 155 start-page: 1801 year: 1995 end-page: 1807 article-title: Benzodiazepines and the risk of hip falling leading to femur fractures. publication-title: Arch Intern Med – start-page: 1321 year: 1994 end-page: 1336 – volume: 151 start-page: 1779 year: 1991 end-page: 1783 article-title: Outpatient use of prescription sedative‐hypnotic drugs in the United States, 1970 through 1989. publication-title: Arch Intern Med – volume: 31 start-page: 625 year: 1997 end-page: 632 article-title: Zolpidem: Distinct from triazolam? publication-title: Ann Pharmacother – volume: 40 start-page: 291 year: 1990 end-page: 313 article-title: Zolpidem: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. publication-title: Drugs – year: 1996 – volume: 53 start-page: 19 issue: Suppl year: 1992 end-page: 31 article-title: Comparative clinical profiles of triazolam versus other shorter‐acting hypnotics. publication-title: J Clin Psychiatry – volume: 13 start-page: 81 year: 1999 end-page: 93 article-title: The safety and tolerability of zolpidem—an update. publication-title: J Psychopharmacol – volume: 40 start-page: 373 year: 1987 end-page: 383 article-title: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. publication-title: J Chron Dis – year: 1998 – volume: 32 start-page: 680 year: 1998 end-page: 691 article-title: Beyond benzodiazepines: Alternative pharmacologic agents for the treatment of insomnia. publication-title: Ann Pharmacother – year: 1986 – volume: 13 start-page: 157 year: 1998 end-page: 167 article-title: Safety and tolerance of zolpidem in the treatment of disturbed sleep: A post‐marketing surveillance of 16,944 cases. publication-title: Int Clin Psychopharmacol – volume: 47 start-page: 30 year: 1999 end-page: 39 article-title: Drugs and falls in older people: A systematic review and meta‐analysis: I. Psychotropic drugs. publication-title: J Am Geriatr Soc – volume: 45 start-page: 613 year: 1992 end-page: 619 article-title: Adapting a clinical comorbidity index for use with ICD‐9‐CM administrative databases. publication-title: J Clin Epidemiol – volume: 12 start-page: 814 year: 1993 end-page: 828 article-title: Zolpidem: A nonbenzodiazepine hypnotic for treatment of insomnia. publication-title: Clin Pharm – volume: 5 start-page: 541 year: 1994 end-page: 544 article-title: Internal validation of Medicare claims data. publication-title: Epidemiology – volume: 47 start-page: 749 year: 1999 end-page: 754 article-title: Assessment and control for confounding by indication in observational studies. publication-title: J Am Geriatr Soc – year: 1988 – volume: 342 start-page: 443 year: 1993 end-page: 444 article-title: Zolpidem induced macropsia in anorexic woman. publication-title: Lancet – volume: 61 start-page: 253 year: 1998 end-page: 269 article-title: Behavioral pharmacology of zolpidem relative to benzodiazepines: A review. publication-title: Pharmacol Biochem Behav – volume: 316 start-page: 363 year: 1987 end-page: 369 article-title: Psychotropic drug use and the risk of hip fracture. publication-title: N Engl J Med – volume: 339 start-page: 875 year: 1998 end-page: 882 article-title: Antidepressants and the risk of falls among nursing home residents. publication-title: N Engl J Med – volume: 262 start-page: 3303 year: 1989 end-page: 3307 article-title: Benzodiazepines of long and short elimination half‐life and the risk of hip fracture. publication-title: JAMA – volume: 12 start-page: 21S issue: Suppl. 1 year: 1997 end-page: 29S article-title: General safety profile of zolpidem: Safety in elderly, overdose and rebound effects. publication-title: Eur Psychiatry – volume: 339 start-page: 809 year: 1992 article-title: Psychotic reactions to zolpidem. publication-title: Lancet – volume: 53 start-page: 2638 year: 1996 article-title: Dependence and tolerance with zolpidem. publication-title: Am J Health Syst Pharm – volume: 272 start-page: 1721 year: 1994 end-page: 1722 article-title: Chronic abuse of zolpidem. publication-title: JAMA – start-page: 119 year: 1991 end-page: 128 – volume: 12 start-page: 814 year: 1993 ident: e_1_2_6_16_2 article-title: Zolpidem: A nonbenzodiazepine hypnotic for treatment of insomnia. publication-title: Clin Pharm – ident: e_1_2_6_27_2 – volume: 13 start-page: 81 year: 1999 ident: e_1_2_6_11_2 article-title: The safety and tolerability of zolpidem—an update. publication-title: J Psychopharmacol doi: 10.1177/026988119901300109 – ident: e_1_2_6_6_2 doi: 10.1001/jama.262.23.3303 – ident: e_1_2_6_22_2 doi: 10.1016/S0924-9338(97)80017-X – ident: e_1_2_6_13_2 – ident: e_1_2_6_21_2 doi: 10.1097/00004850-199807000-00002 – volume: 1 start-page: 89 issue: 1 year: 1992 ident: e_1_2_6_36_2 article-title: Neurological adverse event profile in elderly with zolpidem 5 mg and 10 mg: A retrospective evaluation of European phase II and III studies. publication-title: J Sleep Res – volume-title: Clinical Geriatric Psychopharmacology year: 1998 ident: e_1_2_6_38_2 – volume-title: Imidazopyridines in Sleep Disorders year: 1988 ident: e_1_2_6_10_2 – volume: 53 start-page: 19 year: 1992 ident: e_1_2_6_20_2 article-title: Comparative clinical profiles of triazolam versus other shorter‐acting hypnotics. publication-title: J Clin Psychiatry – ident: e_1_2_6_4_2 doi: 10.1111/j.1532-5415.1999.tb01898.x – volume-title: Diseases: Tabular List. Commission on Professional and Hospital Activities year: 1986 ident: e_1_2_6_28_2 – ident: e_1_2_6_12_2 – ident: e_1_2_6_19_2 doi: 10.2165/00003495-199040020-00008 – ident: e_1_2_6_3_2 doi: 10.1056/NEJM199809243391303 – ident: e_1_2_6_23_2 doi: 10.1016/0140-6736(92)91935-2 – volume: 53 start-page: 2638 year: 1996 ident: e_1_2_6_24_2 article-title: Dependence and tolerance with zolpidem. publication-title: Am J Health Syst Pharm doi: 10.1093/ajhp/53.21.2638 – volume-title: Physicians' Current Procedural Terminology year: 1989 ident: e_1_2_6_29_2 – volume: 5 start-page: 541 year: 1994 ident: e_1_2_6_30_2 article-title: Internal validation of Medicare claims data. publication-title: Epidemiology – ident: e_1_2_6_5_2 doi: 10.1056/NEJM198702123160702 – ident: e_1_2_6_17_2 doi: 10.2165/00002018-199513040-00005 – ident: e_1_2_6_9_2 doi: 10.2165/00003088-199529030-00002 – start-page: 119 volume-title: Observation and Inference: An Introduction to the Methods of Epidemiology year: 1991 ident: e_1_2_6_35_2 – ident: e_1_2_6_34_2 doi: 10.1111/j.1532-5415.1999.tb01603.x – ident: e_1_2_6_14_2 doi: 10.1016/S0091-3057(98)00102-6 – ident: e_1_2_6_18_2 doi: 10.1345/aph.17111 – ident: e_1_2_6_26_2 doi: 10.1016/0140-6736(93)92862-N – ident: e_1_2_6_32_2 doi: 10.1016/0021-9681(87)90171-8 – ident: e_1_2_6_31_2 doi: 10.1016/0895-4356(92)90133-8 – start-page: 1321 volume-title: Principles of Geriatric Medicine and Gerontology year: 1994 ident: e_1_2_6_37_2 – ident: e_1_2_6_7_2 doi: 10.5694/j.1326-5377.1993.tb121839.x – ident: e_1_2_6_8_2 doi: 10.1001/archinte.155.16.1801 – ident: e_1_2_6_15_2 doi: 10.1177/106002809703100518 – ident: e_1_2_6_2_2 doi: 10.1001/archinte.151.9.1779 – ident: e_1_2_6_25_2 doi: 10.1001/jama.272.22.1721 – volume-title: SAS release 6.12 year: 1996 ident: e_1_2_6_33_2 |
SSID | ssj0012088 |
Score | 2.170826 |
Snippet | OBJECTIVES: The widespread use of sedative‐hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer... OBJECTIVES: The widespread use of sedative‐hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer... The widespread use of sedative-hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer regimens that... Although benzodiazepines have been shown to increase fall and fracture risk, zolpidem, a nonbenzodiazepine hypnotic has been advocated as a safer alternative.... |
SourceID | proquest pubmed pascalfrancis crossref wiley istex |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1685 |
SubjectTerms | Aged Aged, 80 and over Aging - drug effects Antidepressive Agents - adverse effects Antipsychotic Agents - adverse effects Benzodiazepines - adverse effects Benzothiadiazines Biological and medical sciences Case-Control Studies Diuretics Elderly people Falls Female Fractured hips Fractures hip fracture Hip Fractures - chemically induced Hip Fractures - surgery Humans Hypnotics Hypnotics and Sedatives - adverse effects Length of Stay Male Medical sciences Neuropharmacology Odds Ratio older Older people Pharmacology. Drug treatments Prescription drugs Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology Psychotropic Drugs - adverse effects Pyridines - adverse effects Retrospective Studies Risk Factors sedative-hypnotics Sodium Chloride Symporter Inhibitors - adverse effects USA Zolpidem |
Title | Zolpidem Use and Hip Fractures in Older People |
URI | https://api.istex.fr/ark:/67375/WNG-XN3N89PZ-B/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1532-5415.2001.49280.x https://www.ncbi.nlm.nih.gov/pubmed/11844004 https://www.proquest.com/docview/210384632 https://www.proquest.com/docview/57818923 https://www.proquest.com/docview/72439346 |
Volume | 49 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 0002-8614 databaseCode: DR2 dateStart: 20010101 customDbUrl: isFulltext: true eissn: 1532-5415 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0012088 providerName: Wiley-Blackwell |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlhdJL3w83bapD6c3GetnSsS3dLIFsQ9ulSy5Cr4WwwRviXQj99dXIXqcuKYTSm8GWhUYzmm-kTzMIvRPUUaZCyKM34TlXPOTS2JAHWvmKBmt94uYcz6rpnB8txKLnP8FdmC4_xLDhBpaR1mswcGPbsZELBnn8iYAwjxRcUVkWgCcJE-nE9uuQSYrQUsoBCUeXNCb13Pijkae6C0K_AuakaaPwll3Vi5tg6RjlJjc1eYhWuwF27JRVsd3Ywv38I_fj_5HAI_SgR7P4Q6d-j9Gd0DxB94778_qnqDhdn6cStHjeBmwaj6dnF3gCN7O2Mc7HZw3-AmXC8Ukisj9D88nn75-meV-hIXdCyDKnzHmleGm5ocJFKOBIiIBJhHrJLFXGQ_joKPGldMQrZknpQ229MlKZyhD2HO016ya8RNgbHyNN5T1ssChwksbXTFjIF-jZkmSo3s2Gdn36cqiica5_C2OiODSIA4prEp3Eoa8yRIaWF10Kj1u0eZ8mfGhgLldAgauF_jE71IsZm0l1cqo_ZuhgpBHXPQA8iPqfof2diuh-eWg1hbT0vGI0Q2-Ht9Gu4bDGNGG9bXVcSYmM6PvvX9Q0gknGqwy96DTvuu8YtsPaHGWW9OfWw9ZHh9_S46t_brmP7ieaXmL8vEZ7m8tteBNx28YeJIv8Bf1mLak |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwED-hTQJeYHyNsLHlAfGWKLbjJH6Eja6MNUywimovlh270rQqndZWmvjr8TlpRtCQJsRbpORi-Xwfv7PPdwDvOK0oE9ZGzpukUSpSGxVK28jSzGTUam18bs6ozIbj9HjCJ207ILwL09SH6DbcUDO8vUYFxw3pvpZzhoX8Ccc4j8SpoEUSO0C5icd1qKWH37paUoQmRdFhYeeU-mk9d_6p56s2ke03mDupFo5906bvxV3AtI9zvaMaPIXZeopNfsplvFrquPr5R_XH_8SDLXjSAtrwQyOBz-CBrZ_Dw1F7ZP8C4vP5zHehDccLG6rahMOLq3CAl7NWLtQPL-rwK3YKD099LvtLGA8-nR0Mo7ZJQ1RxXiQRZZURIk10qiivHBqoiHWYidt8yjQVymAEWVFikqIiRjBNEmNzbYQqhMoUYa9go57X9jWERhkXbApjcI9FoJ9UJmdcY8lAw6YkgHy9HLJqK5hjI42Z_C2SceyQyA7sr0mkZ4e8CYB0lFdNFY970Lz3K94RqOtLzILLufxRHslJycpCnJ7LjwHs9UTidgRECE4FAthZy4hsLcRCUqxMn2aMBrDfvXWqjec1qrbz1UI6Y0oKB8D__kVOHZ5kaRbAdiN6t2O7yB3Ns-OZF6B7T1seH333j2_-mXIfHg3PRify5HP5ZQce-6w9nwC0CxvL65V962DcUu959fwF63gxxQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9swED9GC2Uv-97qdWv9MPbmYH3Z1uO-0qxbvbAtLPRFSJYCJcUJTQJlf_10suPOo4My9mawZaHTne530k93AK8ErSiTziXem_CES-6SQhuXOJrZjDpjbODmnJbZaMJPpmLa8p_wLkyTH6LbcEPLCOs1GvjSzvpGLhjm8ScCwzwy4JIW6cDjyV2e-WALAdLXLpUUoWlRdFDY-6Q-q-fGP_Vc1S5K_Qqpk3rlpTdryl7chEv7MDf4qeF9mG9H2NBT5oPN2gyqn38kf_w_IngA91o4G79p9O8h3HH1I9g7bQ_sH8PgbHERatDGk5WLdW3j0fkyHuLVrI0P9OPzOv6CdcLjcWCyP4HJ8MP3d6OkLdGQVEIUaUJZZaXkqeGaispjgYo4j5iEy2fMUKktxo8VJTYtKmIlMyS1LjdW6kLqTBP2FHbqRe32Ibba-lBTWos7LBK9pLY5EwYTBlo2IxHk29lQVZu_HMtoXKjf4hgvDoXiwOqaRAVxqKsISNdy2eTwuEWb12HCuwb6co4cuFyoH-WxmpasLOT4TL2N4LCnEdc9ID7wBhDBwVZFVLs-rBTFvPQ8YzSCo-6tN2w8rdG1W2xWyi-lpPDw--9f5NSjScazCJ41mnfdt4_bcXH2Mgv6c-thq5Pjb-Hx-T-3PIK98fuh-vyx_HQAdwNlL7B_XsDO-nLjXnoMtzaHwTh_AQ0xMHQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Zolpidem+Use+and+hip+fractures+in+older+people&rft.jtitle=Journal+of+the+American+Geriatrics+Society+%28JAGS%29&rft.au=WANG%2C+Philip+S&rft.au=BOHN%2C+Rhonda+L&rft.au=GLYNN%2C+Robert+J&rft.au=MOGUN%2C+Helen&rft.date=2001-12-01&rft.pub=Blackwell&rft.issn=0002-8614&rft.volume=49&rft.issue=12&rft.spage=1685&rft.epage=1690&rft_id=info:doi/10.1111%2Fj.1532-5415.2001.49280.x&rft.externalDBID=n%2Fa&rft.externalDocID=13413514 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-8614&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-8614&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-8614&client=summon |